Gracell Biotechnologies Inc ADR (GRCL) concluded trading on Wednesday at a closing price of $10.25, with 6.42 million shares of worth about $65.77 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 222.33% during that period and on Wednesday the price saw a gain of about 0.05%. Currently the company’s common shares owned by public are about 95.93M shares, out of which, 71.38M shares are available for trading.
However, the stock later moved at a day high price of 10.28, or with a gain of 0.05%. Stock saw a price change of -0.87% in past 5 days and over the past one month there was a price change of 2.30%. Year-to-date (YTD), GRCL shares are showing a performance of 2.09% which increased to 369.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.40 but also hit the highest price of $10.44 during that period. The average intraday trading volume for Gracell Biotechnologies Inc ADR shares is 1.36 million. The stock is currently trading 0.50% above its 20-day simple moving average (SMA20), while that difference is up 13.54% for SMA50 and it goes to 106.21% higher than SMA200.
Gracell Biotechnologies Inc ADR (NASDAQ: GRCL) currently have 95.93M outstanding shares and institutions hold larger chunk of about 40.39% of that.
The stock has a current market capitalization of $983.28M and its 3Y-monthly beta is at -0.35. It has posted earnings per share of -$1.02 in the same period. It has Quick Ratio of 7.73 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GRCL, volatility over the week remained 1.12% while standing at 1.27% over the month.
Analysts are in expectations that Gracell Biotechnologies Inc ADR (GRCL) stock would likely to be making an EPS of -$0.14 in the current quarter, while forecast for next quarter EPS is -$0.21 and it is -$0.54 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.19 which is -$0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.3 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.61% while it is estimated to increase by 6.84% in next year.
Coverage by Stifel stated Gracell Biotechnologies Inc ADR (GRCL) stock as a Buy in their note to investors on October 19, 2023, suggesting a price target of $11 for the stock. On March 27, 2023, Wells Fargo Resumed their recommendations, while on December 08, 2022, H.C. Wainwright Initiated their ratings for the stock with a price target of $6. Stock get a Buy rating from Citigroup on September 22, 2022.
